Core Viewpoint - Palantir Technologies has shown strong stock performance this year, with only one S&P 500 stock outperforming it, yet analysts remain skeptical about its near-term prospects despite significant investments from billionaires Ken Griffin and Izzy Englander [1][4]. Group 1: Stock Performance and Investor Sentiment - Palantir's stock has gained significantly, trailing only NRG Energy, which has seen a 76% increase year-to-date [1]. - Ken Griffin's Citadel Advisors tripled its position in Palantir, owning 441,755 shares by the end of 2024 [1]. - Izzy Englander's Millennium Management quadrupled its stake to 1,312,758 shares in the first quarter of 2025 [2]. Group 2: Analyst Opinions and Valuation Concerns - The consensus 12-month price target for Palantir is approximately 22% below its current share price, indicating a lack of optimism among analysts [4]. - Among 25 analysts, only one rated Palantir as a "strong buy," while seven recommended selling the stock [5]. - Palantir's shares are trading at nearly 244 times forward earnings, raising concerns about its high valuation [6]. Group 3: Growth Prospects and Market Expectations - Analysts express doubts about Palantir's growth prospects justifying its high valuation, with a PEG ratio of 4.22, which is considered unattractive [7]. - Some investors, like Dan Ives from Wedbush, predict that Palantir's market cap could triple to $1 trillion in the next two to three years, suggesting stronger growth expectations [9]. - Concerns are raised that no tech stock has sustained such a high multiple as Palantir's, indicating potential market challenges [10]. Group 4: Potential Hedging Strategies - The option strategies employed by Griffin and Englander may indicate a more cautious approach, suggesting that their bullish stance might be hedged [12].

Core Viewpoint - Pfizer is a pharmaceutical company with solid growth potential and a high dividend yield, making it a stock worth considering for investment [1][6]. Company Overview - Pfizer has a market value of approximately $133 billion and has been in operation since 1849, offering multiple treatments and a robust pipeline of products [3]. - The company currently has 108 candidates in its pipeline, with 47 in phase 1, 28 in phase 2, and 30 in phase 3, focusing significantly on oncology and various vaccines [4]. Current Products - Major medications include the COVID-19 vaccine, Paxlovid, Prevnar, Ibrance, and Xtandi [5]. Investment Considerations Reasons to Invest - The stock offers a dividend yield of 7.3%, generating around $730 for every $10,000 invested, with a commitment to maintain and grow this dividend over time [6][9]. - Pfizer's valuation is low, with a forward-looking P/E ratio of 8, below its five-year average of 10, and a price-to-sales ratio of 2.1, lower than its five-year average of 3.1 [11]. - The company has strong growth prospects, particularly in oncology, bolstered by the acquisition of Seagen for $43 billion [11]. Reasons Against Investment - The payout ratio is 122%, indicating that the company is paying out more than its earnings in dividends, which may not be sustainable [11]. - Pfizer has experienced average annual losses of 18.6% over the past three years, with revenue declining from $100.3 billion in 2022 to $63.6 billion in 2024 [11]. - Several key products are losing patent protection, and concerns have arisen regarding the safety of its weight-loss drug candidate [11]. - Ongoing tariff wars and government efforts to lower drug costs may pose additional challenges for the company [11].

Company Overview - Blue Owl Capital Corporation (NYSE: OBDC) is a Business Development Company (BDC) [1] Financial Performance - In Q1, Blue Owl Capital delivered a total NAV return of 2%, which is in line with the median return in the coverage [1]

Core Viewpoint - PVH Corp. has lowered its FY25 guidance and second-quarter adjusted EPS guidance, leading to a decline in share price despite beating quarterly earnings and revenue estimates [1][2]. Financial Performance - PVH reported quarterly earnings of $2.30 per share, exceeding the analyst consensus estimate of $2.25, and quarterly revenue of $1.98 billion, surpassing the Street estimate of $1.93 billion [1]. - The company has revised its fiscal 2026 adjusted EPS guidance from a range of $12.40 to $12.75 down to $10.75 to $11, compared to the analyst estimate of $12.52 [2]. Analyst Insights - Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating with a $90 price target, noting that while PVH posted a first-quarter beat, its operating margin fell short due to gross margin pressures [2][3]. - Needham analyst Tom Nikic reiterated a Buy rating with a $115 price target, suggesting that the guidance cut may exert selling pressure but believes the downward revision was largely priced in [4]. - Evercore ISI Group analyst Michael Binetti reaffirmed an Outperform rating while trimming the price forecast from $105 to $95 [6]. Market Reaction - PVH shares are down 16.71% at $67.35 following the announcement [6]. - Several analysts have adjusted their price targets and ratings post-results, with Wells Fargo cutting its forecast from $100 to $80 and BMO Capital lowering its forecast from $93 to $84 [5].

Core Insights - Newmont Corporation (NEM) achieved a record first-quarter free cash flow of $1.2 billion, a significant improvement from a negative $74 million in the same period last year, driven by enhanced operational efficiency and a strong Tier 1 portfolio [1][7] - Despite the strong first-quarter performance, sustainability concerns exist for the second quarter due to non-core asset divestitures, increased tax payments, and higher capital expenditures [2][3][7] - The anticipated decline in free cash flow is attributed to long-term growth initiatives rather than deteriorating fundamentals, supported by a solid balance sheet [3][7] Peer Comparisons - Barrick Mining Corporation reported a free cash flow of $375 million for the first quarter, reflecting a nearly 12-fold year-over-year increase due to higher operating cash flows from increased gold and copper prices [4] - Agnico Eagle Mines Limited generated first-quarter free cash flows of $594 million, up approximately 50% year over year, supported by strong gold prices and operational results [5] Market Performance - Newmont's shares have increased by 48.5% year to date, compared to a 53.9% rise in the Zacks Mining – Gold industry, largely driven by the rally in gold prices [6] - The Zacks Consensus Estimate for NEM's earnings in 2025 and 2026 implies year-over-year increases of 20.1% and 11.7%, respectively, with EPS estimates trending higher over the past 60 days [8] - NEM is currently trading at a forward 12-month earnings multiple of 12.59, approximately 10% below the industry average of 13.97 [9]

Group 1 - Moretus Research provides high-quality equity research focused on U.S. public markets, aiming to deliver clarity, conviction, and alpha for serious investors [1] - The research framework identifies companies with durable business models, mispriced cash flow potential, and intelligent capital allocation, emphasizing a structured and repeatable approach [1] - Valuation methods are based on sector-relevant multiples tailored to each company's business model and capital structure, prioritizing comparability, simplicity, and relevance [1] Group 2 - Research coverage focuses on underappreciated companies experiencing structural changes or temporary dislocations, where disciplined analysis can yield asymmetric returns [1] - Moretus Research aims to elevate the standard for independent investment research by providing professional-grade insights and actionable valuation [1]

Group 1 - The article emphasizes the importance of investing in companies that demonstrate growth in revenue, earnings, and free cash flow [1] - It highlights the preference for companies with excellent growth prospects and favorable valuations [1] - The focus is on steadily growing companies with high free cash flow margins, dividend stocks, and those with generous share repurchase programs [1]

Core Viewpoint - Costco Wholesale has demonstrated significant stock performance with a 600% increase over the past decade, but future growth may not justify its current high valuation [1][2][8] Business Model - Costco operates a membership warehouse model, selling items in bulk at low margins while generating most profits from membership fees [4] - The company has built strong brand power, allowing it to attract customers without spending on marketing [5] Recent Performance - In the latest quarter, Costco reported an 8% increase in net sales and a 5.8% increase in comparable-store traffic year-over-year [6][7] - Paid memberships rose by 6.8%, indicating a robust customer base despite concerns about consumer spending [7] Valuation Concerns - The stock's price-to-earnings (P/E) ratio has increased from a range of 25-35 pre-pandemic to nearly 60 today, suggesting a disconnect between stock price and earnings growth [8][10] - Analysts project long-term earnings growth of 9% to 10% annually, which may not be sufficient to support the current high valuation [10][11] Future Projections - If Costco's earnings grow at a 10% annualized rate, projected earnings per share for fiscal years 2026 to 2030 would be $19.80, $21.78, $23.96, $26.35, and $28.99 respectively [12][15] - Applying a historical P/E of 30 to the projected earnings could suggest a share price of $870 by 2030, while the current trading price is $1,040, indicating potential overvaluation [13][14]

Entel SA (ENTEL.SN) Trimming Estimates Post-1Q25 27 May 2025 | 5:20PM BRT | ENTEL.SN | | --- | | 12m Price Target: Ch$3,450 | | Price: Ch$2,791 | | Upside: 23.6% | We incorporate 1Q25 earnings as well as updated macro/FX assumptions, lowering estimates particularly in Chile, given i) somewhat more-conservative ARPU assumptions amid continued competitive pressure from AMX and WOM in mobile, though we already assumed some increased competition this year; ii) weaker-than-expected fiber trends, with management ...

Investment Rating - The investment rating for Meiji Holdings is Neutral, with a 12-month target price revised to ¥3,400 from ¥3,500, reflecting a slight decrease in operating profit estimates [1][18][22]. Core Insights - The report indicates that operating profits for FY3/25 are expected to miss guidance, primarily due to anticipated shortfalls in sales across domestic milk, the dairy overseas business, and the vaccines/animal health business [1][17]. - The company has a significant market share in Japan for dairy products, chocolate, and protein products, but its growth prospects are considered to be adequately reflected in the current share price [22]. - The report highlights the importance of monitoring input costs, price hikes, and sales recovery in the food segment, as well as growth in the pharmaceuticals segment, particularly in vaccines and overseas business expansion [19][22]. Financial Estimates - FY3/26 operating profit estimates have been adjusted by -0.1% for the overall company, with specific adjustments of +¥0.7 billion for the food segment and +¥0.2 billion for the pharmaceuticals segment, while adjustments account for a decrease of -¥1.0 billion [1][17]. - Sales estimates for FY3/26 are projected at ¥1,192.2 billion, reflecting a year-on-year growth of 3.3% [3][20]. - The net profit for FY3/26 is estimated at ¥53.9 billion, with an EPS of ¥202.1 [3][20]. Segment Performance - The food segment's operating profit is expected to be ¥70.7 billion for FY3/26, while the pharmaceuticals segment is projected at ¥25.7 billion [20]. - Key areas of focus for the food segment include dairy, chocolate, and nutrition, with specific sales estimates for dairy at ¥273.5 billion and chocolate at ¥177.2 billion for FY3/26 [20]. - The pharmaceuticals segment is anticipated to see growth driven by vaccines and the expansion of the overseas CMO/CDMO business, despite challenges from drug price revisions [19][22].